James Huang Joins KPCB as Partner in China

Pharmaceutical industry executive James Huang has joined Kleiner Perkins Caufield & Byers as a partner in Shanghai, China.

Huang, who will advise on life science investment opportunities in China, joins KPCB from Vivo Ventures, a venture capital firm specializing in life science investments, where he was a managing partner.

Prior to Vivo, he was president of biopharmaceutical company Anesiva and held senior roles with Tularik, Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp.

Commenting on the appointment, Tina Ju, a managing partner and co-founder of KPCB China, said: “With his extensive business development and operating experience, James will be a tremendous asset for innovators looking to develop successful pharmaceutical companies in China”.



Join the discussion